Subtype
Rectal Neoplasm
CI-CAN-00006564Explore in graph →
Non-malignant434 active trials1 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006564Explore in graph →
Clinical trials
1,773 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07198165 | SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC | recruiting | Phase 2 | 104 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07175636 | QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer | not yet recruiting | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07161115 |
| Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer(REFIRT) |
| not yet recruiting |
| Phase 2 |
| 60 |
| Longhao LiOTHER |
| 1 |
| Sep 15, 2025 |
| clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT01876901 | Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR)(CASCADOR) | completed | Phase 2 | 124 | Institut BergoniéOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06770270 | Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)(PUCRT) | recruiting | Phase 2 | 68 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07150949 | Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) | recruiting | Phase 2 | 138 | Fudan UniversityOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05576480 | SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer(SPARC) | recruiting | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT07134218 | Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 180 | Changhai HospitalOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT05732389 | Immunotherapy in Patients With Early dMMR Rectal Cancer(RESET-R) | recruiting | Phase 2 | 39 | Odense University HospitalOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07108127 | Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer(NePHera) | recruiting | Phase 2 | 24 | Peking Union Medical College HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05591534 | Endorectal Brachytherapy for Rectal Cancer(ICUREC) | suspended | Phase 2 | 31 | University Hospital, BordeauxOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07095439 | Efficacy and Toxicity of Total Neoadjuvant Sandwich Treatment Via Short Course Radiotherapy in the Treatment of Stage II and III Rectal Cancer Patients | recruiting | Phase 2 | 38 | Ain Shams UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06940388 | Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.(TOTAL) | recruiting | Phase 2 | 134 | brenner baruchOTHER | 2 | Jul 24, 2025 | clinicaltrials |
| NCT07059949 | Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer(Union-mRC) | not yet recruiting | Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jul 11, 2025 | clinicaltrials |
| NCT05663775 | Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)(IMPACT 1) | recruiting | Phase 2 | 20 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07040098 | Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer(STELLARIII) | recruiting | Phase 2 | 228 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT02368886 | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 123 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06057831 | PET/MRI in Rectal Cancer | not yet recruiting | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 0 | Jun 18, 2025 | clinicaltrials |
| NCT04554836 | MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab | completed | Phase 2 | 6 | TheraOpOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT01493206 | A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer | completed | Phase 2 | 32 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06895577 | Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer- | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT05965531 | Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy(TASLARC) | recruiting | Phase 2 | 65 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06923345 | Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I) | recruiting | Phase 2 | 80 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06718543 | Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer(TRIUNITE-03) | recruiting | Phase 2 | 100 | fan liOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06919510 | A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 0 | Apr 9, 2025 | clinicaltrials |
| NCT06056804 | Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer | active not recruiting | Phase 2 | 20 | Beijing Friendship HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT00200200 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer | completed | Phase 2 | 73 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06872606 | Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer(SCRIPBOT) | not yet recruiting | Phase 2 | 33 | Sir Run Run Shaw HospitalOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT01643070 | Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases | completed | Phase 2 | 38 | Asan Medical CenterOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04380337 | Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer | completed | Phase 2 | 38 | Stanford UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06840665 | MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06812728 | Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients | recruiting | Phase 2 | 100 | Menoufia UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04696757 | Non-OpeRative MANagement of Rectal Cancer Patients(NORMANDY) | completed | Phase 2 | 18 | Kangbuk Samsung HospitalOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT01652196 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | completed | Phase 2 | 56 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | completed | Phase 2 | 16 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT05792735 | Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer(NeoCaCRT) | completed | Phase 2 | 27 | Shenzhen People's HospitalOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT06802666 | Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 45 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT02000050 | Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)(COLORE) | completed | Phase 2 | 52 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06793137 | Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer | recruiting | Phase 2 | 100 | AC Camargo Cancer CenterOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03127007 | Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer(R-IMMUNE) | completed | Phase 1 / Phase 2 | 45 | Grand Hôpital de CharleroiOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06108596 | Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail(PICS) | completed | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04518280 | Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer(TORCH) | completed | Phase 2 | 130 | Fudan UniversityOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06765616 | Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer | recruiting | Phase 2 | 31 | Feng TianOTHER_GOV | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06760520 | Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 40 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jan 8, 2025 | clinicaltrials |
| NCT06751394 | Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer(TRACER) | not yet recruiting | Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05601505 | Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer(CINTS-R) | recruiting | Phase 2 | 470 | Peking Union Medical College HospitalOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02861300 | CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | completed | Phase 1 / Phase 2 | 50 | David Bajor, MDOTHER | 1 | Dec 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 30, 2025source: clinicaltrials